Literature DB >> 6117348

Formal thought disorder, the type-token ratio and disturbed voluntary motor movement in schizophrenia.

T C Manschreck, B A Maher, D N Ader.   

Abstract

Little work has been done to determine objective, reliable differences in formal characteristics of the actual utterances of thought-disordered and non-thought-disordered subjects. The type-token ratio (TTR), a quantitative measure of repetition in language, correlated highly with clinical judgments of thought disorder when spoken language was examined, and statistically differentiated thought-disordered from non-thought-disordered schizophrenics and psychiatric and normal controls. Elicited and spontaneous motor abnormalities were associated with reduced TTRs both in schizophrenics and in affective subjects with motor disturbance. The TTR is a reliable, objective indicator of language deviance and thought disorder, and strongly associated with motor disturbances.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117348     DOI: 10.1192/bjp.139.1.7

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Computational linguistic analysis applied to a semantic fluency task to measure derailment and tangentiality in schizophrenia.

Authors:  Luca Pauselli; Brooke Halpern; Sean D Cleary; Benson Ku; Michael A Covington; Michael T Compton
Journal:  Psychiatry Res       Date:  2018-02-17       Impact factor: 3.222

2.  Quantifying incoherence in speech: an automated methodology and novel application to schizophrenia.

Authors:  Brita Elvevåg; Peter W Foltz; Daniel R Weinberger; Terry E Goldberg
Journal:  Schizophr Res       Date:  2007-04-16       Impact factor: 4.939

3.  Language in schizophrenia Part 1: an Introduction.

Authors:  Gina R Kuperberg
Journal:  Lang Linguist Compass       Date:  2010-08

4.  Motor stereotypies and cognitive perseveration in non-human primates exposed to early gestational irradiation.

Authors:  L D Selemon; H R Friedman
Journal:  Neuroscience       Date:  2013-06-13       Impact factor: 3.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.